Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Latest News Updates

2nd Closed Expert Meeting of the Editorial Board 2015

22 May, Amsterdam, The Netherlands

Imaging of atherosclerotic vascular disease: The challenges and impact of therapy

Imaging of atherosclerotic vascular disease: The challenges and impact of therapy

Professor Raimund Erbel Director, Department of Cardiology, West German Heart Centre Essen

Posted on 16 July 2015 | Posted by Raimund Erbel | Posted in Webcasts, 2nd Closed Scientific Expert Meeting of the Editorial Board, 2nd Closed Expert Meeting of the Editorial Board 2015

Very low LDL: Mechanism and potential clinical impact

Very low LDL: Mechanism and potential clinical impact

Professor Eran Leitersdorf MD Professor of Medicine

Posted on 16 July 2015 | Posted by Eran Leitersdorf | Posted in Webcasts, 2nd Closed Scientific Expert Meeting of the Editorial Board, 2nd Closed Expert Meeting of the Editorial Board 2015

PCSK9 Clinical trials: What’s new?

PCSK9 Clinical trials: What’s new?

Dr Michel Farnier MD PhD Clinician based at Point Medical, Dijon, France

Posted on 16 July 2015 | Posted by Michel Farnier | Posted in Webcasts, 2nd Closed Scientific Expert Meeting of the Editorial Board, 2nd Closed Expert Meeting of the Editorial Board 2015

PCSK9: What do we still need to know about its biology and therapeutic applications

PCSK9: What do we still need to know about its biology and therapeutic applications

Dr Nabil Seidah PhD, OQ, MRSC, MC Director, Laboratory of Biochemical Neuroendocrinology

Posted on 16 July 2015 | Posted by Nabil G. Seidah | Posted in Webcasts, 2nd Closed Scientific Expert Meeting of the Editorial Board, 2nd Closed Expert Meeting of the Editorial Board 2015

Genotypic and phenotypic variation in FH – relevance to cardiovascular risk

Genotypic and phenotypic variation in FH – relevance to cardiovascular risk

Professor Frederick Raal FRCP, FRCPC, FCP(SA), MMED, PhD Director, Carbohydrate & Lipid Metabolism Research Unit

Posted on 2 July 2015 | Posted by Frederick J. Raal | Posted in Webcasts, 2nd Closed Scientific Expert Meeting of the Editorial Board, 2nd Closed Expert Meeting of the Editorial Board 2015

Statin Intolerance: What is it? What are therapeutic options?

Statin Intolerance: What is it? What are therapeutic options?

Professor Erik Stroes MD PhD Chairman, department of Vascular Medicine

Posted on 2 July 2015 | Posted by Erik Stroes | Posted in Webcasts, 2nd Closed Scientific Expert Meeting of the Editorial Board, 2nd Closed Expert Meeting of the Editorial Board 2015

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

Lib Therapeutics

Novartis

Sanofi

© Copyright 2024 PCSK9 Forum. All rights reserved